$RGLS
Regulus Therapeutics Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513440494 Filed on November 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $5.454M $6.118M $2.809M
YoY Change 68.44% 117.8% -26.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.880M $1.920M $1.090M
YoY Change -2.59% 76.15% 19.78%
% of Gross Profit
Research & Development $8.230M $7.106M $5.248M
YoY Change 46.7% 35.4% 35.43%
% of Gross Profit
Depreciation & Amortization $360.0K $370.0K $260.0K
YoY Change 28.57% 42.31% 13.04%
% of Gross Profit
Operating Expenses $10.12M $9.023M $6.341M
YoY Change 34.15% 42.3% 32.6%
Operating Profit -$2.905M -$3.532M
YoY Change -17.75% 263.0%
Interest Expense $70.00K $7.000K $110.0K
YoY Change -12.5% -93.64% 13.4%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$1.950M -$2.169M -$5.691M
YoY Change -71.57% -61.89% 446.69%
Income Tax -$20.00K -$5.000K -$6.000K
% Of Pretax Income
Net Earnings -$1.927M -$2.164M -$5.685M
YoY Change -71.97% -61.93% 444.02%
Net Earnings / Revenue -35.33% -35.37% -202.39%
Basic Earnings Per Share -$0.05 -$0.05 -$15.98
Diluted Earnings Per Share -$0.11 -$0.07 -$15.98
COMMON SHARES
Basic Shares Outstanding 41.78M shares 40.15M shares 355.7M shares
Diluted Shares Outstanding 41.56M shares 355.7M shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.0M $123.9M $30.90M
YoY Change 16.21% 300.97%
Cash & Equivalents $17.81M $33.49M $17.43M
Short-Term Investments $96.20M $90.40M $13.50M
Other Short-Term Assets $3.100M $1.300M $500.0K
YoY Change 287.5% 160.0%
Inventory
Prepaid Expenses
Receivables $100.0K $100.0K $3.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $117.2M $125.3M $34.36M
YoY Change 18.45% 264.64%
LONG-TERM ASSETS
Property, Plant & Equipment $3.768M $3.981M $3.144M
YoY Change 13.84% 26.62%
Goodwill
YoY Change
Intangibles $1.128M $1.145M $1.124M
YoY Change -2.25% 1.87%
Long-Term Investments
YoY Change
Other Assets $987.0K $178.0K $2.096M
YoY Change 689.6% -91.51%
Total Long-Term Assets $5.883M $5.304M $6.364M
YoY Change 28.2% -16.66%
TOTAL ASSETS
Total Short-Term Assets $117.2M $125.3M $34.36M
Total Long-Term Assets $5.883M $5.304M $6.364M
Total Assets $123.1M $130.6M $40.72M
YoY Change 18.88% 220.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.172M $1.140M $649.0K
YoY Change 276.85% 75.65%
Accrued Expenses $3.013M $1.705M $2.100M
YoY Change 357.9% -18.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $10.37M $13.53M $13.41M
YoY Change -18.78% 0.9%
LONG-TERM LIABILITIES
Long-Term Debt $11.30M $13.90M $17.40M
YoY Change 11.88% -20.11%
Other Long-Term Liabilities $1.459M $1.558M $18.30M
YoY Change 90.22% -91.49%
Total Long-Term Liabilities $1.459M $1.558M $35.70M
YoY Change 90.22% -95.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.37M $13.53M $13.41M
Total Long-Term Liabilities $1.459M $1.558M $35.70M
Total Liabilities $29.61M $36.14M $49.18M
YoY Change -28.53% -26.51%
SHAREHOLDERS EQUITY
Retained Earnings -$79.09M -$77.16M -$53.54M
YoY Change 30.9% 44.11%
Common Stock $42.00K $42.00K $0.00
YoY Change 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.46M $94.45M -$51.15M
YoY Change
Total Liabilities & Shareholders Equity $123.1M $130.6M $40.72M
YoY Change 18.88% 220.68%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$1.927M -$2.164M -$5.685M
YoY Change -71.97% -61.93% 444.02%
Depreciation, Depletion And Amortization $360.0K $370.0K $260.0K
YoY Change 28.57% 42.31% 13.04%
Cash From Operating Activities -$9.310M -$4.430M $230.0K
YoY Change -1195.29% -2026.09% -87.57%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$340.0K $10.00K
YoY Change -55.81% -3500.0%
Acquisitions
YoY Change
Other Investing Activities -$6.170M -$27.16M $8.500M
YoY Change -86.08% -419.53% -240.96%
Cash From Investing Activities -$6.370M -$27.49M $8.510M
YoY Change -85.76% -423.03% -241.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 46.25M 3.760M
YoY Change -100.01% 1130.05% -3860.0%
NET CHANGE
Cash From Operating Activities -9.310M -4.430M 230.0K
Cash From Investing Activities -6.370M -27.49M 8.510M
Cash From Financing Activities -10.00K 46.25M 3.760M
Net Change In Cash -15.69M 14.33M 12.50M
YoY Change -167.83% 14.64% -392.74%
FREE CASH FLOW
Cash From Operating Activities -$9.310M -$4.430M $230.0K
Capital Expenditures -$190.0K -$340.0K $10.00K
Free Cash Flow -$9.120M -$4.090M $220.0K
YoY Change -812.5% -1959.09% -88.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
5000000
CY2012Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
10800000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41777326 shares
CY2013Q2 us-gaap Share Price
SharePrice
9.81
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17426000
CY2013Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41774442 shares
CY2013Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8182756 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.78
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4160000 shares
CY2013Q3 us-gaap Share Price
SharePrice
9.43
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41774442 shares
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7138000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13527000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-44000
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1228000
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171608000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1140000
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1558000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
94446000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77160000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9454000
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1705000
CY2013Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
5400000
CY2013Q3 us-gaap Liabilities
Liabilities
36144000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
42000
CY2013Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
13921000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130590000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
178000
CY2013Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
95000
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1145000
CY2013Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
123790000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3981000
CY2013Q3 us-gaap Assets
Assets
130590000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33490000
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
90413000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1288000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
125286000
CY2013Q3 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
90443000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9175000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35831808 shares
CY2012Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7124739 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.11
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4720000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35831808 shares
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
17756000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12768000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-52000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1348000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
122528000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
311000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
767000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
62093000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60419000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10451000
CY2012Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
10134000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658000
CY2012Q4 us-gaap Liabilities
Liabilities
41425000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103518000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1154000
CY2012Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
96911000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3310000
CY2012Q4 us-gaap Assets
Assets
103518000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40552000
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
57548000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
829000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
98929000
CY2012Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
57590000
dei Trading Symbol
TradingSymbol
RGLS
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
361000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37367368000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.91
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Deferred Revenue</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.</p> </div>
us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.65 pure
us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.085 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0032 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19016000
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1256232 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3875462 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
720000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.44
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Use of Estimates</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</p> </div>
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.80
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37367368000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
201000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
608000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-3787000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Profit Loss
ProfitLoss
-16741000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
50390000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16745000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57000
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
20000
us-gaap Revenues
Revenues
14115000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
512000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
84000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16733000
us-gaap Gain Loss On Investments
GainLossOnInvestments
6000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13140000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
46000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
95000
us-gaap Interest And Other Income
InterestAndOtherIncome
207000
us-gaap Net Income Loss
NetIncomeLoss
-16741000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1018000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
68000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-120000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5545000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46478000
us-gaap Profit Loss
ProfitLoss
-10532000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9287000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10560000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11615000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
851000
us-gaap Interest Expense
InterestExpense
25000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
829000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46562000
us-gaap Share Based Compensation
ShareBasedCompensation
2524000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7062000
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
50000
us-gaap Operating Expenses
OperatingExpenses
27255000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
996000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2524000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34524000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21710000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
16520000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-41.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-41.03
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
256682000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9572000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16523462 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256682000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
724000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-331000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
44000
us-gaap Income Taxes Paid
IncomeTaxesPaid
207000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1307000
us-gaap Revenues
Revenues
9462000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1738000
us-gaap Interest Paid
InterestPaid
32000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-56000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
326000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10488000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8271000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
185000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
3000000
us-gaap Interest And Other Income
InterestAndOtherIncome
74000
us-gaap Net Income Loss
NetIncomeLoss
-10532000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-311000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
55000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
302000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2998000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3469000
us-gaap Share Based Compensation
ShareBasedCompensation
732000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
10000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8251000
us-gaap Operating Expenses
OperatingExpenses
17733000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-28000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-527000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
73000
us-gaap Interest Expense
InterestExpense
294000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
102000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
5000000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
741000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
732000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14354000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14735000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
24550000
CY2013Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5175000 shares
CY2013Q3 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
9.50
CY2013Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
45800000
CY2012 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
7000
CY2012 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
49000
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.98
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.98
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
355735000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16545674 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
355735000 shares
CY2012Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-331000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5691000
CY2012Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1738000
CY2012Q3 us-gaap Revenues
Revenues
2809000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5675000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3532000
CY2012Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
20000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-5685000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1093000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
6341000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
CY2012Q3 us-gaap Interest Expense
InterestExpense
110000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
414000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5248000
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41555660000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3041033 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40154812000 shares
CY2013Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
671000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
37000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2169000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2835000
CY2013Q3 us-gaap Revenues
Revenues
6118000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2127000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2905000
CY2013Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
72000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2164000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1917000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
9023000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
CY2013Q3 us-gaap Interest Expense
InterestExpense
7000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
978000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7106000

Files In Submission

Name View Source Status
0001193125-13-440494-index-headers.html Edgar Link pending
0001193125-13-440494-index.html Edgar Link pending
0001193125-13-440494.txt Edgar Link pending
0001193125-13-440494-xbrl.zip Edgar Link pending
d599924d10q.htm Edgar Link pending
d599924dex311.htm Edgar Link pending
d599924dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20130930.xml Edgar Link completed
rgls-20130930.xsd Edgar Link pending
rgls-20130930_cal.xml Edgar Link unprocessable
rgls-20130930_def.xml Edgar Link unprocessable
rgls-20130930_lab.xml Edgar Link unprocessable
rgls-20130930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending